Tue, Jul 22, 2014, 3:43 PM EDT - U.S. Markets close in 17 mins.


% | $
Click the to save as a favorite.

Acura Pharmaceuticals, Inc. Message Board

mitchpit11 108 posts  |  Last Activity: Jul 14, 2014 12:17 PM Member since: Feb 6, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The company will no longer sell single-ingredient pseudoephedrine, often sold under the Sudafed brand name. The step follows similar ones by Rite Aid Corp. and Walgreen Co. in the state, said a spokesman for Democratic Sen. Joe Manchin, who has lobbied companies to stop selling the products....
    In addition to stopping sales of the product in its 50 stores in West Virginia, CVS also will drop it from 40 stores located within 15 miles of the state border, in Kentucky, Maryland, Ohio, Pennsylvania and Virginia. It is the first time the company has made such a move.
    CVS will continue to sell in the 90 stores a formulation of the medicine that is resistant to methods used by meth labs. Earlier this year, the company cut the amount of pseudoephedrine products that can be purchased by an individual in a year to half of the limit permitted under West Virginia law.

  • mitchpit11@gmail.com mitchpit11 Jul 11, 2014 4:46 PM Flag

    This move to Japan might be a brilliant one by ISCO, if this is what they though about:

    1. Japan has one of the oldest populations of all countries.
    2. 120M+people with per capita income of $38K, thus quite rich.
    3. FDA equivalent in Japan is probably less stringent and would allow ISCO's stem cell technology to enter the market quickly.
    4. Partnering with a large company and marketing selling into not only Japan, but Asia too.

    The news about Japan might involve more then meets the eye.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Jul 11, 2014 3:29 PM Flag

    Sapphire glass is a new technology that is entering mainstream. That is no speculation.
    Wouldn't you want to have sapphire glass instead of your regular glass areas: in cars, at home, with electronics etc...?
    Sooner or later somebody will approach GTAT just like Apple did.
    Neither Goldman nor anybody else can predict when will that happen.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com by mitchpit11 Jul 11, 2014 3:05 PM Flag

    Looks the same as Q1 sans $3M cash burned and dead 301 study.
    Stock is dead too, no volume these days.
    Whatever shareholders value is left, is now trapped thanks to no news, no progress
    and in general nothing positive Bob and Pete can inform us about..

    In short, ACUR is on autopilot towards bankruptcy, UNLESS news on partnership is

    We expect more amateur moments from ACUR clowns during upcoming CC.

  • mitchpit11@gmail.com mitchpit11 Jul 11, 2014 2:46 PM Flag

    It is worth outlining that sapphire glass technology is going to spread, not only with iPhone 6 this September, but with other phone manufactures and into other areas as well.
    Thus, GTAT with current valuation looks extremely cheap.

    Sentiment: Strong Buy

  • Reports from the ETNews in Korea claim Samsung is meeting with Sapphire glass manufactures to test product samples and review production possibilities, after it rejected the idea of using it last year due to high production costs.

    Apple was the first company to adopt Sapphire glass with small pieces for the iPhone’s camera lens and home button, but it’s taking the glass to revolutionary levels thanks to a new plant in Arizona churning out millions of sheets for the iPhone 6 display.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com by mitchpit11 Jun 3, 2014 3:57 PM Flag

    ACUR finds itself in a weak position after starting 2013 on a very promising note, with Oxecta in the hands of PFE and Nexafed just being introduced to the market.

    A major strategic mistake by the management was wanting to go alone with Nexafed. With apparently $0 marketing dollars and adopting small chain approach to introduce Nexafed, year and a half later the drug is in danger of becoming irrelevant. Bob and Pete simply did not recognize forces they are against: big pharma and their well lubed legislative influence and competition from other companies.
    Valuable time was lost.

    Instead of forcefully looking for a partner for Nexafed while cash was at hand and preserving shareholders value by selling ACUR, Bob and Pete stubbornly wanted to act alone, giving themselves hefty bonuses and pay rises while erasing almost 50% of shareholders value. ACUR burns $3M per quarter and income is anecdotal. Q2 might show the true figures for Nexafed, probably sales in the range of $50K.

    Moreover, Board of Directors did not help either being stuffed by cronies of this ineffective duo.

    PFE dropped ACUR from its lineup, probably recognizing amateurs they were dealing with and on which they spent some $70M in the last few years.

    And speaking of amateurs, what CEO would give go ahead for such an ineffective results like 301 test to be
    presented to FDA!? Why even present and advertise something that is not at least 90% effective!?

    In short: ACUR is running out of time, out of cash, out of ideas how to make tamper resistant product and definitely they have no management talent whatsoever.

    The only hope is a deal with somebody, either Nexafed or Oxecta and before Q2. Otherwise, ACUR stock will
    drop below $1 once Q2 results are published.

  • ...in the meantime insiders are doing unprecedented purchases of stock...looks like partnership with somebody is not far away....

  • mitchpit11@gmail.com by mitchpit11 May 7, 2014 7:40 PM Flag

    "The first quarter is weak, and we think the market is overvaluing the quarter, rather than looking at the strategic vision of AOL," said Laura Martin, an analyst with Needham and Co.

    AOL executives said on a conference call with analysts that the first quarter tended to be soft because of seasonality.

    Sentiment: Strong Buy

  • Reply to

    Bob & Pete HUMM

    by abrcomm May 6, 2014 2:56 PM
    mitchpit11@gmail.com mitchpit11 May 6, 2014 5:20 PM Flag

    Well, both of these guys are behaving like they are gonna live 1000's of years and 4-5 quarters (when, BTW company burned $12-15M) are just blip on the screen. Pete even used term "very early stage".
    I wonder how long was the early stage for a product like Viagra...lol...

    The only thing they can reasonably do to increase prospects of the company is to find a partner for Oxecta, who is going to pump millions. I think, market is there, they have a product and they should be able to find one. That can save the company from going bankrupt.

  • Reply to

    Any News On The Conference This AM

    by lyle19651965 May 6, 2014 1:27 PM
    mitchpit11@gmail.com mitchpit11 May 6, 2014 5:07 PM Flag

    The only interesting point is Oxecta's market size. Bob mentioned that at a cost of $0.50/pill the market size is $800M. PFE priced Oxecta $2.47/pill, so it was in the billions.
    ACUR would like cheaper price, and still $800M/year have plenty of room to make profit.
    Apart from that, there are no firm negotiation as of yet, except signing CA agreements and such.
    So, ACUR just started to engage potential partners. Bob is hoping a deal by the year end.
    I would assume, that deal would include some upfront payment in millions to ACUR and other goodies, similar what they got from PFE. If they can find something like that it would be great!!!

  • OK. So let's try with lemonade stand business.
    You pay $80/day a team of 2 kids to sell lemonade with cost of material $20, total $100/day.
    Let's say, very very conservatively, during the day, kids can sell 1 lemonade every 30 min, and
    lemonade costing $1.
    8 hours a day would yield $16. For those $8M that would be $1.28M in sales!!!

    On this extremely simple example, we can see the sheer ineptness of ACUR management.
    $8M burned in 2 quarters, and only $39,000 in sales!!!
    Not even 7-years old selling lemonade would be able to do this poorly.

  • Reply to

    ACUR Very Good in Filing Useless 8K's

    by mitchpit11 May 5, 2014 5:16 PM
    mitchpit11@gmail.com mitchpit11 May 5, 2014 11:15 PM Flag

    OK. Here is my attempt to collect $10 from you..lol...:

    1. Let's start with Q4 2013: ACUR shipped some $300K of Nexafed for Q4 '13.
    Did not recognize any revenue since pharmacies had "right of return".
    Pete was trying to hide the real sales, and obviously succeeded for Q4.

    2. Now, check this from today's news:
    During the 1st quarter 2014 we recognized revenue of $39 thousand for shipments to customers where the right of return no longer existed either because a pricing allowance was accepted in exchange for forfeiting the right of return or because information became available on pharmacy's reorder activity with their drug wholesaler. During the first quarter 2014 we shipped $42 thousand of NEXAFED®.
    Wow....so, after those $300K was shipped in Q4 '13, only $42K was shipped in Q4 '14!!!
    This is truly catastrophic. It means Nexafed is not selling, ACUR is nor expanding those sales.
    Finally, Pete has to recognize some revenue, and $39K was cashed. That is all.

    Frankly, I am not surprised with such performance for a product with 0 advertisements and
    promotion. I saw if first hand in Publix pharmacy.

    In summary, for 2 quarters, or half a year, ACUR shipped $342K of Nexafed. What is truly disappointing, new orders are decreasing dramatically.

  • This is how it might look like, case for GURE:

    SHOUGUANG, China, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Gulf Resources, Inc. (GURE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today reported that the United States District Court for the Central District of California Western Division entered an Order and Final Judgment approving the settlement and dismissing the class-action lawsuit against Gulf Resources and a number of its current directors and officers.

    Under the terms of the settlement, the class-action lawsuit will be dismissed in return for the payment of a total settlement amount of $2.125 million, which did not have any effect on the company's operation due to its purchased D&O insurance.

    Mr. Xiaobin Liu, CEO of the Company, commented: "We are pleased to have reached final approval of the settlement by the Court, which we believe is in the best interests of the Company and its shareholders, even there is no admission of any wrongdoing or admission of any liability on the part of the Company or any of its current officers or directors. We look forward to closing this chapter and focusing on achieving our business goals for year 2014."

    Sentiment: Strong Buy

  • mitchpit11@gmail.com by mitchpit11 May 5, 2014 5:16 PM Flag

    Like this on:


    Results of Operations and Financial Condition, Financial Statements an

    Item 2.02 Results of Operations and Financial Condition

    On May 5, 2014 we issued a press release disclosing the financial results for our first quarter ended March 31, 2014. A copy of our press release is being furnished as Exhibit 99.1 hereto.


    So, you file 8-K when you issue press release!? Oh, nobody is doing that....

    ACUR should have written something like this:

    Item 2.02 Results of Operations and Financial Condition

    On May 5, 2014 we issued a press release disclosing the financial results for our first quarter ended March 31, 2014. The 8-K is really issued because we want to appear compliant with SEC, while we are in fact scared that truth will come out ACUR is in reality just investors cash burning organization that will never be profitable and that fools investors with appearance of selling useless drugs. Pfizer read us, and regretted
    ever being in business with us.
    We do not advertize nor we do anything to promote our products, it is much better to have good salary and healthy bonus. All of our energy goes to plots of how to fool investors and funds in giving us their money.
    We ourselfs never believed in ACUR, which can be easily checked with total absence of insiders purchases. We are not that foolish to invest in our #$%$.
    Other than that, we are a great company :).
    Please SEC do not go after us. Look, we just filed another useless 8-K.
    A copy of our press release is being furnished as Exhibit 99.1 hereto.

  • $4.2M burned in 1Q and sales only $42,000...
    Cash went mostly to salaries and bonuses...
    while Pete is playing "revenue recognition game" with investors:
    "Hey guys, I sold millions of #$%$, but can only recognize $42,000; vote for my bonus :)))) "

  • Reply to

    ACUR - No news is.....no news..

    by unpredictable_trader May 5, 2014 1:15 PM
    mitchpit11@gmail.com mitchpit11 May 5, 2014 2:19 PM Flag

    I am sorry Lyle, but that is reality.
    The only reason ACUR is alive today is because they got some $75M from PFE and
    also endless stock dilutions, totaling some $300M spent so far on the whole
    enterprise in the last 15 years.
    For that money and time, ACUR has little to show, certainly not in terms of the ability to generate revenue.
    The only thing it can show are Bob, Pete and Scully making a good living out of this
    whole mirage and scam that is allowed to continue under the current SEC regulations
    and at the expense of shareholders, or whatever unlucky funds they talked into investing.
    I would love to be wrong, but somehow after disappointments with Nexafed and now Oxecta, I have a feel this might be one of those that will go under....ever so slowly...

  • Reply to

    ACUR - No news is.....no news..

    by unpredictable_trader May 5, 2014 1:15 PM
    mitchpit11@gmail.com mitchpit11 May 5, 2014 1:58 PM Flag

    With ACUR it is a pretty straightforward situation:
    Either ACUR finds a partner and starts selling their #$%$ or
    they burn all cash on their over bloated salaries and bonuses before filing for BK.
    I think time is running out...

  • mitchpit11@gmail.com mitchpit11 May 3, 2014 6:49 PM Flag

    BTW, Lee resigned as CEO of LLEN.

    And again, more fantasy, this is what you are saying:
    Lee will command from prison.
    All these guys that went to China: Fong, Pei, Yang and Borich are Lee's puppets.
    Lee is a true master as his destiny is inseparable from LLEN's.
    He will do with LLEN whatever he pleases.
    SEC will stop bringing other charges.
    I can create any fantasy as you, like this one:
    Fong is sick of Lee and severes all relations as now Fong's reputation as ex Bush Gov official is on the line. His life legacy
    is now in question.
    The fact Lee is prison does not bode well in China and customers and mine workers and partners there now stick to Fong and BOD.
    LLEN elects new CEO and runs normally.
    Stock recovers, trades on OTC in $3-5 range and get listing in Taiwan.
    Lee is released from prison at the age of 75 and retires in Taiwan...

    I mean madaniels57, where does it stop? You don't know any
    of the #$%$ you are saying will happen for sure, as if you would, you would have shorted the hell out of LLEN. Why didn't you short?
    You said you have no position, but with such crystal ball you possess in your brain, it is foolish not to do it?

    So tell me, what other companies you see so clearly as you see LLEN, both Long and Short cases. I am listening....

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 May 3, 2014 5:35 PM Flag

    Hellooooo....Lee is in jail in US, pending trial and you are already jumping to his retirement in Taiwan.

    If the company is fraud, as you are alleging, Lee will get many many years in jail. It will be not only CFO misrepresentation, but fraud for everything, 10-15 years....

    But what you are saying, Lee will somehow escape all this and flee to Taiwan, while LLEN will collapse. There are many high quality people at LLEN right now, they should take charge and continue.

    Lastly, any public company is a vehicle to get to working capital, otherwise there would be no need to be public company.

    Sentiment: Strong Buy

1.01-0.02(-1.94%)3:39 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.